NDAORALTABLET
Approved
Mar 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Complement Factor D Inhibitors
Pharmacologic Class:
Complement Factor D Inhibitor
Clinical Trials (5)
Danicopan PMS in Korea
Started Mar 2026
8 enrolled
Paroxysmal Nocturnal Hemoglobinuria
Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data
Started Jan 2026
50 enrolled
Paroxysmal Nocturnal HemoglobinuriaPNH
Long-term Safety of Danicopan: IPIG Registry-based Cohort Study
Started Aug 2025
50 enrolled
Paroxysmal Nocturnal HemoglobinuriaPNH
Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis
Started Aug 2025
6 enrolled
Paroxysmal Nocturnal HemoglobinuriaPNHExtravascular Hemolysis
A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
Started Oct 2022
80 enrolled
Paroxysmal Nocturnal Hemoglobinuria
Loss of Exclusivity
LOE Date
Aug 2, 2038
151 months away
Patent Expiry
Aug 2, 2038
Exclusivity Expiry
Mar 29, 2031